AFT Pharmaceuticals announced the licensing of Maxigesic IV, the intravenous form of its proprietary pain relief medicine, for Brazil, the largest pharma market in South America and the tenth largest pharma market in the world. AFT has now out-licensing or its own distribution arrangements for Maxigesic IV in eight of the top Pharma markets in the world: USA, Germany, France, Italy, UK (AFT Pharma UK Ltd), Canada (AFT Pharma Canada Ltd), Spain and now Brazil.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.85 NZD | -6.25% |
|
-9.81% | -18.57% |
06-04 | New Zealand Shares Flat; Scott Technology Adds Meat Cutter to Brand Portfolio | MT |
06-03 | AFT Pharmaceuticals Partners with Alexso to Bring Pain Relief Drug to US Market | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.57% | 183M | |
+51.63% | 796B | |
+41.51% | 628B | |
-5.10% | 358B | |
+19.90% | 331B | |
+9.95% | 301B | |
+17.66% | 244B | |
+3.39% | 228B | |
+10.75% | 214B | |
+6.99% | 165B |
- Stock Market
- Equities
- AFT Stock
- News AFT Pharmaceuticals Limited
- AFT Pharmaceuticals Limited Licenses Maxigesic IV in Brazil